1. Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev. 1999, 170: 85-100.
2. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995, 154: 3961-3968.
3. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997, 18: 175-182. 10.1016/S0167-5699(97)84664-6.
4. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA: T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J. 2000, 6: 69-77.
5. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996, 2: 551-555.